Chronic lymphocytic leukaemia cells exhibit functional heterogeneity in the unfolded protein response: a proteomic study
Ontology highlight
ABSTRACT: Genomic, epigenomic, and transcriptomic studies have provided only a partial explanation of disease heterogeneity in chronic lymphocytic leukaemia (CLL). Since mRNA and protein expression do not always correlate, CLL heterogeneity was investigated using global cellular proteomics. Sequential Windowed Acquisition of All THeoretical fragments Mass Spectrometry (SWATH-MS) was applied to CLL samples obtained from patients undergoing initial treatment with fludarabine-containing chemoimmunotherapy. Two independent proteomic datasets were generated: one compared pre-treatment samples from 32 patients who achieved an optimal versus suboptimal therapy response; the other compared paired samples from 16 patients collected before treatment and at disease progression. eIF2 signalling, which is pivotal to the unfolded protein response (UPR), was identified by Ingenuity Pathway Analysis as the most enriched pathway in both datasets. eIF2 signalling was also identified as the top pathway in a fludarabine-resistant CLL cell line established from HG3 cells. Measurement of key components of the eIF2 signalling pathway by Western blotting showed that fludarabine-resistant HG3 cells expressed higher levels of PERK, which phosphorylates the regulatory eIF2α subunit, and lower levels of BiP, an HSP70 molecular chaperone that inactivates PERK but preferentially binds to misfolded proteins during ER stress. The PERK inhibitor, GSK2606414, sensitised resistant, but not sensitive, HG-3 cells to fludarabine without affecting background cell viability or cytotoxicity induced by venetoclax. These findings provide the first evidence of functionally important heterogeneity in the UPR of CLL cells and, in doing so, illustrate the value of global cellular proteomics as an investigative tool in assessing differential patient response to therapy.
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): B Cell
DISEASE(S): Chronic Lymphocytic Leukemia
SUBMITTER:
Rosalind Jenkins
LAB HEAD: Rosalind Jenkins
PROVIDER: PXD058183 | Pride | 2025-08-04
REPOSITORIES: Pride
ACCESS DATA